Anika Therapeutics, Inc. Variable Lease, Cost
Anika Therapeutics, Inc. (ANIK) reported Variable Lease, Cost of $3.16 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-03-03
- Anika Therapeutics, Inc. variable lease, cost for the quarter ending 2020-12-31 was $60.00K, a 1.64% decline year-over-year.
- Anika Therapeutics, Inc. variable lease, cost for the quarter ending 2020-09-30 was $67.00K, a 55.81% increase year-over-year.
- Anika Therapeutics, Inc. variable lease, cost for the quarter ending 2020-06-30 was $74.00K, a 23.33% increase year-over-year.
- Anika Therapeutics, Inc. variable lease, cost for the quarter ending 2020-03-31 was $63.00K, a 21.15% increase year-over-year.
- Anika Therapeutics, Inc. variable lease, cost for fiscal 2025 was $3.16M, a 17.55% decline from fiscal 2024.
- Anika Therapeutics, Inc. variable lease, cost for fiscal 2024 was $3.83M, a 2.27% increase from fiscal 2023.
- Anika Therapeutics, Inc. variable lease, cost for fiscal 2023 was $3.75M, a 806.78% increase from fiscal 2022.
- Anika Therapeutics, Inc. variable lease, cost for fiscal 2022 was $413.00K, a 29.47% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month | Variable Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.16M 10-K · filed 2026-03-03 | ||||
| 2024-12-31 | $3.83M 10-K · filed 2026-03-03 | $497.00K 10-K · filed 2025-03-17 | |||
| 2023-12-31 | $3.75M 10-K · filed 2026-03-03 | $425.00K 10-K · filed 2024-03-15 | |||
| 2022-12-31 | $413.00K 10-K · filed 2025-03-17 | ||||
| 2021-12-31 | $319.00K 10-K · filed 2024-03-15 | ||||
| 2020-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $127.00K derived: sum of 2 quarters · filed 2023-03-16 | $201.00K derived: sum of 3 quarters · filed 2023-03-16 | $264.00K 10-K · filed 2023-03-16 | |
| 2020-09-30 | $67.00K 10-Q · filed 2020-11-05 | $141.00K derived: sum of 2 quarters · filed 2020-11-05 | $204.00K 10-Q · filed 2020-11-05 | $265.00K derived: sum of 4 quarters · filed 2022-03-11 | |
| 2020-06-30 | $74.00K 10-Q · filed 2020-08-07 | $137.00K 10-Q · filed 2020-08-07 | $198.00K derived: sum of 3 quarters · filed 2022-03-11 | $241.00K derived: sum of 4 quarters · filed 2022-03-11 | |
| 2020-03-31 | $63.00K 10-Q · filed 2020-05-22 | $124.00K derived: sum of 2 quarters · filed 2022-03-11 | $167.00K derived: sum of 3 quarters · filed 2022-03-11 | $227.00K derived: sum of 4 quarters · filed 2022-03-11 | |
| 2019-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $104.00K derived: sum of 2 quarters · filed 2022-03-11 | $164.00K derived: sum of 3 quarters · filed 2022-03-11 | $216.00K 10-K · filed 2022-03-11 | |
| 2019-09-30 | $43.00K 10-Q · filed 2020-11-05 | $103.00K derived: sum of 2 quarters · filed 2020-11-05 | $155.00K 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $60.00K 10-Q · filed 2020-08-07 | $112.00K 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | $52.00K 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |